{"Title":"Aileron Therapeutics","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"15","Founded":"","Address":"","Phone":"(617) 995-0900","Web_address":"http://www.aileronrx.com","Market_cup":"$220.7mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-18.8 mil (last 12 months)","Symbol":"ALRN","Exchange":"NASDAQ","Shares":"3.8","Price_range":"$15.00 - $15.00","Est_volume":"$56.3 mil","Manager":"BofA Merrill Lynch/ Jefferies","CO_managers":"William Blair/ Canaccord Genuity","Exp_to_trade":"6/29/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Our lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2."}